Cynthia Matossian, MD, FACS; Anthony DeFino , 2025-04-30 13:28:00
April 30, 2025
2 min watch
LOS ANGELES — In this Healio Video Perspective from the ASCRS meeting, Marguerite B. McDonald, MD, discusses the efficacy of Miebo for dry eye disease in patients with and without cataracts.
The post hoc analysis found that Miebo (perfluorohexyloctane ophthalmic solution, Bausch + Lomb) demonstrated statistically significant improvements in total corneal fluorescein staining at 2 weeks and 8 weeks after starting treatment compared with the control group.
“Miebo is something we should all consider if we want a preop cataract patient to improve quickly,” McDonald said.
Sources/Disclosures
Collapse
McDonald MB, et al. Perfluorohexyloctane ophthalmic solution in patients with dry eye disease and cataract: Post hoc analysis of pooled data from pivotal trials. Presented at: American Society of Cataract and Refractive Surgery meeting; April 25-28, 2025; Los Angeles.
Disclosures:
McDonald reports consulting for Bausch + Lomb.
